Quercis Pharma develops proprietary PDI inhibitors and Mast Cell Activation Modulators to prevent venous thromboembolism in high-risk cancer patients and individuals with sickle cell disease. Their lead drug candidate, Kinisoquin™, effectively reduces coagulation markers without increasing bleeding risk, addressing significant unmet medical needs in these populations.
Funding
$150M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer patients and individuals with sickle cell disease face a heightened risk of venous thromboembolism (VTE), a dangerous condition involving blood clot formation in the veins. Current treatments to prevent VTE can increase the risk of bleeding, creating a significant clinical challenge. There is an unmet need for effective antithrombotic therapies that do not elevate bleeding risk in these vulnerable populations.
Solution
Quercis Pharma is developing a portfolio of Protein Disulfide Isomerase (PDI) inhibitors and Mast Cell Activation Modulators designed to prevent VTE without increasing bleeding risk. Their lead drug candidate, Kinisoquin™, features a patented isoquercetin formulation and is administered orally. Kinisoquin™ aims to address the underlying blood clotting mechanism, offering a potentially safer alternative to traditional blood-thinning agents. Clinical studies have demonstrated that Kinisoquin™ effectively reduces coagulation markers in high-risk cancer and sickle cell disease patients. The company is also exploring the potential of PDI inhibitors for anti-cancer, antiviral, and immunomodulatory applications.
Target Audience
The primary target audience includes high-risk cancer patients and individuals with sickle cell disease who are susceptible to venous thromboembolism.
Features
- Kinisoquin™: A proprietary, orally available drug candidate containing a patented isoquercetin formulation.
- PDI Inhibition: Targets the protein disulfide isomerase pathway to modulate blood clotting.
- Mast Cell Activation Modulation: Aims to regulate mast cell activity to prevent thrombosis.
- Reduced Bleeding Risk: Designed to lower the risk of bleeding compared to current standard-of-care antithrombotics.
- Clinical Validation: Demonstrated reduction in coagulation markers in Phase 2 clinical trials involving cancer and sickle cell disease patients.
- Potential for Broad Application: Investigating use in cancer, viral illnesses, and other diseases associated with thrombosis.